The obesity paradox in beyond total mesorectal excision surgery for locally advanced and recurrent rectal cancer

被引:0
作者
Daniel L. H. Baird
Constantinos Simillis
Gianluca Pellino
Christos Kontovounisios
Shahnawaz Rasheed
Paris P. Tekkis
机构
[1] The Royal Marsden Hospital,Department of Colorectal Surgery
[2] Imperial College London,Department of Surgery and Cancer
[3] Chelsea and Westminster Hospital,Department of Colorectal Surgery
来源
Updates in Surgery | 2019年 / 71卷
关键词
Rectal cancer; Beyond TME; Body Mass Index;
D O I
暂无
中图分类号
学科分类号
摘要
The objective is to investigate preoperative body mass index (BMI) in patients receiving beyond total mesorectal excision (bTME) surgery. The primary end point is length of postoperative stay. Secondary end points are length of intensive care stay, postoperative morbidity and overall survival. BMI is the most commonly used anthropometric measurement of nutrition and studies have shown that overweight and obese patients can have improved surgical outcomes. Patients who underwent a bTME operation for locally advanced or recurrent rectal cancer were put into three BMI (kg/m2) groups of normal weight (18.5–24.9), overweight (25–29.9) and obese (≥ 30) for analysis. Included are 220 consecutive patients from a single centre. The overall length of stay, in days ± standard deviation (range), for normal weight, overweight and obese patients was 21.14 ± 16.4 (6–99), 15.24 ± 4.3 (7–32) and 19.10 ± 9.8 (8–62) respectively (p = 0.002). The mean ICU length of stay was 5.40 ± 9.1 (1–69), 3.37 ± 2.4 (0–19) and 3.60 ± 2.4 (1–14), respectively (p = 0.030). There was no significant difference between the three groups in terms of postoperative morbidity or overall survival. Patients with a normal weight BMI in this cohort have a significantly longer length of stay in ICU and in hospital than overweight or obese patients. This is seen with no significant difference in morbidity or overall survival.
引用
收藏
页码:313 / 321
页数:8
相关论文
共 244 条
  • [1] Hong YS(2014)Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial Lancet Oncol. 15 1245-1253
  • [2] Nam BH(2010)Cancer statistics, 2010 CA Cancer J Clin 60 277-300
  • [3] Kim KP(2013)Multivisceral resection in colorectal cancer: a systematic review Ann Surg Oncol 20 2929-2936
  • [4] Kim JE(2013)Consensus statement on the multidisciplinary management of patients with recurrent and primary rectal cancer beyond total mesorectal excision planes Br J Surg 100 E1-E33
  • [5] Park SJ(2005)Total mesorectal excision for rectal cancer: difference in outcome for low and high rectal cancer Dis Colon Rectum. 48 2224-2231
  • [6] Park YS(1999)Pelvic resection of recurrent rectal cancer: technical considerations and outcomes Dis Colon Rectum. 42 1438-1448
  • [7] Jemal A(2009)Total pelvic exenteration for primary and recurrent malignancies World J Surg. 33 1502-1508
  • [8] Siegel R(2017)A systematic review to assess resection margin status after abdominoperineal excision and pelvic exenteration for rectal cancer Ann Surg 265 291-299
  • [9] Xu J(2015)Time trends, improvements and national auditing of rectal cancer management over an 18-year period Colorectal Dis 17 O168-O179
  • [10] Ward E(2009)Magnetic resonance imaging prediction of an involved surgical resection margin in low rectal cancer Dis Colon Rectum 52 632-639